Clinical trials: Cardiovascular Diseases Risk
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to…
- Trial name
- STRENGTH (NCT02104817)
- Testing
- Epanova® (omega-3 carboxylic acids), corn oil control
- Where
- 684 sites in United States, Australia and 20 more
- Volunteers
- 13,078 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Cardiovascular Risk
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already…
- Trial name
- AMBITION 7 (NCT07797335)
- Testing
- Zenagamtide, Insulin glargine U-100
- Where
- 330 sites in United States, Argentina and 14 more
- Volunteers
- 1,778 people
- Sponsor
- Novo Nordisk A/S
Carotid Artery Disease
SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy
The primary objective of this study is to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease.
- Trial name
- NCT00403078
- Where
- 5 sites in United States
- Volunteers
- 21,008 people
- Sponsor
- Cordis US Corp.
Aortic Valve Stenosis
Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)
The investigation concerns a prospective, multicenter, single arm safety and performance study evaluating the Medtronic CoreValve system.
- Trial name
- NCT01051518
- Testing
- Medtronic CoreValve System
- Where
- 9 sites in Canada, Germany and 2 more
- Volunteers
- 126 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Thrombosis, Venous
Hemorrhage Risk Prescribed Arixtra
Arixtra (fondaparinux sodium) was the first selective Factor Xa inhibitor to be marketed. As with all anticoagulants, an important adverse event associated with Arixtra use is haemorrhage.
- Trial name
- NCT01064362
- Testing
- Fondaparinux sodium, Low molecular weight heparin (LMWH)
- Volunteers
- 13,442 people
- Sponsor
- GlaxoSmithKline
Contraception, Female Contraception
A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control
The purpose of the study is to use data from a health care information database to assess the risk of venous thromboembolism (blood clots), myocardial infarction (heart attacks), and stroke among women using a transdermal…
- Trial name
- NCT00377988
- Testing
- Transdermal Contraceptive System, Norgestimate-containing oral contraceptives with EE
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Dyslipidemias, Hypercholesterolemia
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk…
- Conditions
- Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD
- Trial name
- TANDEM (NCT06005597)
- Testing
- Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe
- Where
- 45 sites in United States
- Volunteers
- 407 people
- Sponsor
- NewAmsterdam Pharma
Diabetes Mellitus, Type 2, Obesity
Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study
This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease, Cardiovascular Risk
- Trial name
- NCT07673822
- Testing
- No treatment given
- Where
- South Korea
- Volunteers
- 800,000 people
- Sponsor
- Novo Nordisk A/S
Mitral Valve Regurgitation, Mitral Valve Insufficiency
HighLife™ Transcatheter Mitral Valve Replacement System Study
Multicenter feasibility study of the HighLife™ TMVR system.
- Trial name
- NCT02974881
- Testing
- Transcatheter Mitral Valve Replacement
- Where
- 10 sites in France, Germany
- Volunteers
- 5 people
- Sponsor
- HighLife SAS
Acute Leukemia, Multiple Myeloma
Study of 3D189 in Patients With Hematologic Malignancies
To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies.
- Conditions
- Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome
- Trial name
- NCT05320809
- Testing
- 3D189
- Where
- 4 sites in China
- Volunteers
- 16 people
- Sponsor
- 3D Medicines
Carotid Artery Stenosis
ViVEXX Carotid Revascularization Trial (VIVA)
To evaluate the safety and efficacy of the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System in the treatment of extracranial carotid artery stenosis in patients at high risk for carotid…
- Trial name
- NCT00417963
- Testing
- Carotid Artery Stenting
- Volunteers
- 407 people
- Sponsor
- C. R. Bard
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- MOVE-Lp(a) (NCT07157774)
- Testing
- Muvalaplin
- Where
- 804 sites in United States, Argentina and 26 more
- Volunteers
- 10,450 people
- Sponsor
- Eli Lilly and Company
Cardiac Transplant Failure, Cardiac Transplant Rejection
Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing
The objective of this registry is to observe short and long term clinical outcomes in heart transplant recipients who receive regular AlloMap testing as part of allograft rejection surveillance.
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Trial name
- OAR (NCT01833195)
- Where
- 36 sites in United States
- Volunteers
- 2,444 people, healthy volunteers welcome
- Sponsor
- CareDx
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Cardiac Decompensation
Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices
This is planned as a feasibility study. The objective is to evaluate a specially designed patient adherence and monitoring software on standard mobile devices in remote monitoring of heart failure patients.
- Trial name
- REMOTE-HF-1 (NCT01430936)
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 51 people
- Sponsor
- Aventyn, Inc.
Dyslipidemias, Hyperlipidemias
PLATOREL® STUDY IN CARDIOVASCULAR RISΚ ASSESMENT
Dyslipidemias are a major risk factor for the onset of cardiovascular disease, while early diagnosis and appropriate treatment approaches significantly reduce cardiovascular morbidity and mortality.
- Conditions
- Dyslipidemias, Hyperlipidemias, Risk Factor, Cardiovascular, Quality of Life
- Trial name
- PLATINUM (NCT03329729)
- Testing
- Rosuvastatin
- Where
- Greece
- Volunteers
- 4,700 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Healthy Subjects (HS), Obese Adult Participants at Risk of Cardiovascular Disease
A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969
This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969…
- Trial name
- NCT07581431
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- InSilico Medicine Hong Kong Limited
Pulmonary Embolism
Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
Objective: to evaluate the efficacy and safety of the non-immunogenic recombinant staphylokinase with its single bolus administration in comparison with placebo in normotensive patients with intermediate high-risk pulmonary…
- Trial name
- NCT06362746
- Testing
- Non-immunogenic recombinant staphylokinase
- Where
- 24 sites in Russia
- Volunteers
- 486 people
- Sponsor
- Supergene, LLC
Aortic Aneurysm, Aortic Aneurysm Abdominal
AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation
This study will test how well an artificial intelligence (AI) software called Aorta AIM measures the size of the aorta (the body's main blood vessel) from CT scans.
- Conditions
- Aortic Aneurysm, Aortic Aneurysm Abdominal, Aortic Aneurysm and Dissection, Aortic Aneurysm, Thoracoabdominal
- Trial name
- AI-CARE (NCT07438327)
- Testing
- Aorta AIM Automated Measurement, Expert Radiologist Manual Measurement
- Where
- 3 sites in United States, Brazil
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Aiatella Oy